4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
1 citations
,
November 2020 in “Journal of The American Academy of Dermatology” GSK-36 downregulation with UTMD improves plaque stability in atherosclerosis treatment.
6 citations
,
January 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” New topical treatment using spherical nucleic acids shows promise in reducing psoriasis inflammation.
5 citations
,
November 2024 in “Biomedicine & Pharmacotherapy” The chitosan-peptide system helps cartilage regeneration using fat-derived cells.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.
3 citations
,
November 2023 in “The Journal of Dermatology” January 1980 in “Lluc: revista de cultura i d'idees” Agaricus bisporus β-Glucan particles could effectively treat cervical cancer and offer antimicrobial and antioxidant benefits.
9 citations
,
March 2022 in “Journal of Chemical Information and Modeling” New inhibitors may reduce gut toxicity from cancer drugs.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
9 citations
,
February 2018 in “Journal of dermatological treatment” Methotrexate improved skin condition in 64% of patients with generalized granuloma annulare.
5 citations
,
November 2023 in “The Journal of Dermatology” Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
Baricitinib shows promise for treating alopecia areata with mild side effects.
35 citations
,
August 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.
5 citations
,
September 2024 in “Biomolecules and Biomedicine” Total glucosides of paeony may help treat alopecia areata by reducing inflammation and hair loss.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
January 2023 in “Marmara University Open Access System” Tideglusib with hydrogel improves wound healing in rats.
Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.